11:50 AM EDT, 07/05/2024 (MT Newswires) -- Hutchmed ( HCM ) share were up more than 5% in recent Friday trading after China National Medical Products Administration granted priority review to its new drug application for tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma earlier this week.

The application is supported by results from a mid-stage bridging study in China, and clinical studies conducted by Epizyme outside China. Tazemetostat is developed by Epizyme, an Ipsen company.

Follicular Lymphoma is a subtype of non-Hodgkin's lymphoma.

Price: 18.53, Change: +1.01, Percent Change: +5.76